Evidence map›Paper›PMID 36219779›Full record

ArticleJournal of medicinal chemistry2022

Identification of 5-(Aryl/Heteroaryl)amino-4-quinolones as Potent Membrane-Disrupting Agents to Combat Antibiotic-Resistant Gram-Positive Bacteria.

John R Schultz, Stephen K Costa, Gorakhnath R Jachak, Pooja Hegde, Matthew Zimmerman, Yan Pan, Michaele Josten, Chinedu Ejeh, Travis Hammerstad, Hans Georg Sahl and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

John R SchultzDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Stephen K CostaDepartment of Microbiology & Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire 03755, United States.
Gorakhnath R JachakDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Pooja HegdeDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Matthew ZimmermanCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey 07110, United States.
Yan PanCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey 07110, United States.
Michaele JostenInstitute for Pharmaceutical Microbiology and Institute for Medical Microbiology, Immunology, and Parasitology, University of Bonn, D-53115 Bonn, Germany.
Chinedu EjehDepartment of Microbiology & Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire 03755, United States.
Travis HammerstadDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Hans Georg SahlInstitute for Pharmaceutical Microbiology and Institute for Medical Microbiology, Immunology, and Parasitology, University of Bonn, D-53115 Bonn, Germany.
Pedro M PereiraBacterial Cell Biology Laboratory, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avenida da República (EAN), 2781-901 Oeiras, Portugal.ORCID 0000-0002-1426-9540
Mariana G PinhoBacterial Cell Biology Laboratory, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avenida da República (EAN), 2781-901 Oeiras, Portugal.
Véronique DartoisCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey 07110, United States.ORCID 0000-0001-9470-5009
Ambrose CheungDepartment of Microbiology & Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire 03755, United States.
Courtney C AldrichDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0001-9261-594X
University of Minnesota · USDartmouth College · USHackensack Meridian Health · USUniversidade Nova de Lisboa · PTUniversity of Bonn · DE

Funding

Membrane-active quinoline and quinazoline antibacterials that target Gram positive pathogensR01AI146116 · NIAID · DARTMOUTH COLLEGE · PI CHEUNG, AMBROSE LIN YAU · 2020 to 2024
$3.9M
Optimization of a novel compound that enhances the activity of beta-lactams against Gram+ bacteriaR21AI130540 · NIAID · DARTMOUTH COLLEGE · PI CHEUNG, AMBROSE LIN YAU · 2017 to 2018
$449k
NIAID NIH HHS R01 AI146116NIAID NIH HHS R21 AI130540
6 · The paper itself

Abstract

Nosocomial infections caused by resistant Gram-positive organisms are on the rise, presumably due to a combination of factors including prolonged hospital exposure, increased use of invasive procedures, and pervasive antibiotic therapy. Although antibiotic stewardship and infection control measures are helpful, newer agents against multidrug-resistant (MDR) Gram-positive bacteria are urgently needed. Here, we describe our efforts that led to the identification of 5-amino-4-quinolone

Indexed as

Anti-Bacterial AgentsQuinolonesDrug Resistance, Multiple, BacterialGram-Negative BacteriaGram-Positive BacteriaMicrobial Sensitivity TestsAnti-Bacterial AgentsQuinolones

Identifiers

PMID36219779
PMCPMC9826610
OpenAlexW4304607995

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.